TapewireFind a company

person · Reporting owner

Smith Nicholas Conrad

Disclosed activity across 1 company

Tapewire entity
63408
SEC CIK
0002009130

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Alto Neuroscience, Inc.ANRO · Entity 4755PRESIDENT AND CFOOctober 02, 2026October 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alto Neuroscience, Inc.

Report date October 02, 2026 · Filed October 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect79,060 Reported balance After 2026-10-02 transaction · row 1
1 source row

Row 1 · 2026-10-02 · Exercise / conversion · Acquired 55,000 · Balance 79,060

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2031-09-08Direct57,405 Reported balance After 2026-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-10-02 · Exercise / conversion · Disposed 55,000 · Balance 57,405

F1: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 02, 2026 Filed Oct 5, 2026 20:59 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $2.32 $0.00
Disclosure

SEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · derivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,405

Underlying: Common Stock · 55,000 shares

Expires 2031-09-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
October 02, 2026 Filed Oct 5, 2026 20:59 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionCommon Stock 55,000 $2.32 $127,600.00
Disclosure

SEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 24,056 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 9

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,818

Underlying: Common Stock · 24,056 shares

Expires 2033-12-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 SaleCommon Stock 886 $26.87 $23,806.82
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 6

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 SaleCommon Stock 23,170 $25.78 $597,290.16
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 5

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,946

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Read SEC document
September 30, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionCommon Stock 24,056 $2.35 $56,531.60
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 4

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Read SEC document
September 29, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 54,375 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 8

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,625

Underlying: Common Stock · 54,375 shares

Expires 2034-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
September 29, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 56,455 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 7

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,874

Underlying: Common Stock · 56,455 shares

Expires 2033-12-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
September 29, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 SaleCommon Stock 110,830 $26.58 $2,946,149.56
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 3

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

F2 · price: This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
September 29, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionCommon Stock 54,375 $2.35 $127,781.25
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Read SEC document
September 29, 2026 Filed Oct 2, 2026 05:33 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Exercise / conversionCommon Stock 56,455 $2.35 $132,669.25
Disclosure

SEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 19:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Tax withholdingCommon Stock 2,806 $19.69 $55,250.14
Disclosure

SEC source: 0002009130-26-000002 · wk-form4_1772583322.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

F1 · shares: Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 17:18 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $16.71 $0.00
Disclosure

SEC source: 0002009130-26-000001 · wk-form4_1771021115.xml · derivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-02-10

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 135,000 Not disclosed Strike: $4.20 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 10

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 135,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 135,000 Not disclosed Strike: $2.35 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 9

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2035-02-04

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 90,000 Not disclosed Strike: $14.88 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 8

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 90,000 Not disclosed Strike: $2.35 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 7

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-02-28

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 202,329 Not disclosed Strike: $5.30 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 6

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 202,329 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 202,329 Not disclosed Strike: $2.35 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 5

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,329

Underlying: Common Stock · 202,329 shares

Expires 2033-12-19

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 33,833 Not disclosed Strike: $6.23 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 4

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,833 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 33,833 Not disclosed Strike: $2.35 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 3

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,833

Underlying: Common Stock · 33,833 shares

Expires 2033-04-13

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative 44,962 Not disclosed Strike: $6.23 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,962 shares

Expires 2032-09-21

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
July 03, 2025 Filed Jul 8, 2025 17:20 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 44,962 Not disclosed Strike: $2.35 Not disclosed
Disclosure

SEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,962

Underlying: Common Stock · 44,962 shares

Expires 2032-09-21

F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.

F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
February 05, 2025 Filed Feb 7, 2025 16:22 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 135,000 $0.00 Strike: $4.20 $0.00
Disclosure

SEC source: 0001999480-25-000015 · wk-form4_1738963337.xml · derivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2035-02-04

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 16:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 PurchaseCommon Stock 4,550 $16.56 $75,348.00
Disclosure

SEC source: 0001415889-24-009533 · form4-04012024_040402.xml · nonDerivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,866

Read SEC document
March 28, 2024 Filed Apr 1, 2024 16:15 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 PurchaseCommon Stock 1,600 $15.80 $25,280.00
Disclosure

SEC source: 0001415889-24-009533 · form4-04012024_040402.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,316

Read SEC document
March 01, 2024 Filed Mar 5, 2024 18:00 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantEmployee Stock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $14.88 $0.00
Disclosure

SEC source: 0001415889-24-006823 · form4-03052024_060303.xml · derivative · entry 2

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-02-28

F3 · derivative.exercise_date: 25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 18:00 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantCommon Stock 19,153 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-006823 · form4-03052024_060303.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,716

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person's continuous service through each such vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of common stock.

Read SEC document
February 06, 2024 Filed Feb 7, 2024 16:40 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 PurchaseCommon Stock 1,563 $16.00 $25,008.00
Disclosure

SEC source: 0001415889-24-002940 · form4-02072024_090252.xml · nonDerivative · entry 1

Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,563

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.